Why #BVaccinated?

23 Feb

What is the cost of meningococcal disease?

Who does it impact?

When/for whom should vaccination be recommended?

These are some of the questions that policymakers will ask as they consider how to recommend the new vaccines to protect against serogroup B meningococcal disease.

To find the answers, we believe it is necessary to talk—and listen to—the people directly affected by the disease.

That starts with survivors, but also includes the families and friends of those who get sick; parents, students, faculty, staff and community members who have experienced a case, or an outbreak, on campus; and healthcare professionals who must make a difficult diagnosis and fight a fast-moving disease.

NMA has brought together a cross-section of advocates to give voice to the concerns of all of these groups in a new report: Beyond the Science: Putting a Face on Meningococcal Disease.
cover

As national policy is discussed and implemented, we urge all those involved to consider these perspectives, especially in light of recent cases and outbreaks on college campuses.

For the next few weeks we’ll be making the case that routinely vaccinating our children against this disease is the right thing to do, by taking an in-depth look at the stories and topics covered in this report.

We hope you will follow along, ask questions, share your thoughts and spread the word using #BVaccinated.

Recent College Cases Reinforce Need for Prevention

10 Feb

My son Evan was a pitcher for his college baseball team and in excellent health. Cherice was studying hard to fulfill her dream of becoming a doctor. Caitlin was on the Dean’s list and the captain of her school’s dance team.

When you send your child off to college their future is full of hope and infinite possibilities. Meningococcal disease shouldn’t be one of them, but unfortunately young adults and college students are at increased risk for bacterial meningitis.

In recent weeks, there have been at least five meningococcal disease cases confirmed at college campuses across the United States, with an additional case suspected. At Providence College in Rhode Island, two students were diagnosed with serogroup B meningitis. At the University of Oregon, three students are reported to have meningococcemia; so far one case has been confirmed as serogroup B. This weekend, a student at Yale University in Connecticut was hospitalized for a suspected case of meningitis. We continue to hope for a quick recovery for each of these students.

Many of our M.O.M.s and T.E.A.M. members did not have the opportunity to protect their children or themselves from this terrible disease, but now you do.

We encourage all parents and college students to make sure they are up-to-date with the currently recommended vaccines, including the meningococcal booster before they leave for campus. They should also speak to their healthcare provider about the new vaccines to protect against serogroup B.

For our part, NMA will continue pushing forward until all children are protected from this disease and no family has to go through what our families have.

The Right Thing to Do

26 Jan

All of the advocates featured in our new PSA (learn more about Patti, Jan and the Boyles) have been affected by serogroup B meningococcal disease. They are not alone. Serogroup B accounts for about one-third of all meningococcal disease cases in the U.S., and, like the other strains, it can result in brain damage, hearing loss, kidney failure, limb amputations or even death.

I have heard over and over from parents that they thought their children were fully protected because they were vaccinated with the currently recommended vaccine, which protects against four major strains of meningococcal disease, but does not protect against serogroup B. Thankfully, the U.S. Food and Drug Administration (FDA) recently approved two vaccines for the prevention of serogroup B meningococcal disease in individuals ages 10 to 25. Previously, there had been no approved serogroup B vaccines in the U.S.

Now that we have the tools to fully protect our children:

  • We encourage policymakers to recommend these vaccines for adolescents who are at high risk for infection.
  • We urge parents to vaccinate their children on schedule with the currently recommended meningococcal vaccine and talk to their child’s healthcare provider about getting them the vaccination against serogroup B.
  • We ask you to help us by sharing this public service video through your social media networks and to encourage everyone you know to do the same.

Let’s work together to protect our children from all serogroups of meningococcal disease. It’s the right thing to do.

Running to Honor Those We’ve Lost to Meningitis

14 Jan

“January 1st marked the 10 year anniversary of my battle and survival of bacterial meningitis (meningococcal). My heart and brain were the only two organs that didn’t fail that day. But my heart still breaks every time I see another unvaccinated adolescent or young adult taken in the prime of their lives, unprotected for the battle of a lifetime.”—T.E.A.M. Member Mike LaForgia

Mike is an NMA T.E.A.M. member, meningococcal disease survivor, and avid runner who has completed four marathons, including two as a double amputee.

Mike’s amputations were the result of contracting meningococcal disease at age 39. The infection came on suddenly as he, his wife and his three children were celebrating the 2004 New Year. Mike survived, but lost his right leg below the knee and part of his left foot. He spent two months in the hospital and five months in rehabilitation.

Despite these obstacles, Mike returned to running competitively, only now he runs to raise awareness in honor of those who lost their lives to meningococcal disease. “Through my work with NMA, I’ve met many other families who have been affected by meningococcal disease as well as parents who have lost their children because of it,” says Mike. “Meningococcal disease changed my life, and it’s important to me to honor those who haven’t survived. As a father of three teenagers, an age group that is at higher risk for infection, I encourage parents to speak to their teen’s doctors about routine vaccination against serogroups A, C, W and Y and the newly approved vaccine for serogroup B.”

Mike is now training hard for the Florida Keys Ragnar Relay, which will take place February 6 to 7. He and 11 other team members will each run about 18 miles to cover the distance from Miami to Key West. During this race, as he has before, Mike will be wearing a shirt bearing the names some of the loved ones we’ve lost to this terrible disease.

Help us cheer Mike on by supporting his mission: watch his story, share what you’ve learned and get your children vaccinated. If you would also like to support him with a donation, you can do so here.

Enough is Enough: Preventing Serogroup B Meningococcal Disease

16 Dec

In October, shortly after the approval of the first meningococcal serogroup B vaccine in the U.S., I spoke before the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP). I was joined by two parents, Stephen and Beverly Ross, who lost their daughter to serogroup B meningococcal disease.

The ACIP is a group of medical and public health experts that makes recommendations on how a vaccine should be used in the U.S. Once these recommendations are accepted by the director of the CDC and published, they become part of the official immunization schedule. By sharing our stories with the committee we help put a face on and give a voice to meningococcal disease.

The Ross’ testimony was moving and powerful. I think it is important to share it with all of you. Please take a moment to read the full text below and talk to your child’s healthcare provider about having them vaccinated against serogroup B.

“Good Morning. My name is Stephen Ross and this is my wife Beverly. We’re here today with the National Meningitis Association.

We are the parents of Stephanie Ross. I hope her name still rings a bell with you. She was the Drexel University student who died after contracting serogroup B meningitis in March. She went to bed early one Sunday night because she was feeling tired and only a few hours later was fighting for her life. It was a battle she was destined to lose. She was just 19 years old.

She was an intelligent young woman who was attending Drexel University on a Ben Franklin Fellowship. She was well liked at Drexel as shown by the busload of her fellow students who traveled across the vast state of Pennsylvania the weekend before finals to say goodbye to her. She always went out of her way to assist anyone who asked for help and even some who didn’t. She was quickly growing into a leadership role with her Phi Mu sorority sisters.

When talking about her we always like to share a quote that was posted on one of the websites that she created before her passing in connection with a fundraiser for the Children’s Hospital of Philadelphia. It said: “Thank you for always living your life the way it is supposed to be lived – full of love, laughter, and kindness – to not just friends, but strangers as well.”

Since Stephanie’s passing at least two more college students have died from the serogroup B disease. When will it stop? We need to say enough is enough. As a percentage of all of the students that populate our country’s college campuses we realize that these deaths represent a small number. But when the student is one of yours any number above zero is unacceptable – especially if it could have been prevented. Parents have lots of things to think about when we send our children off to college. We shouldn’t have to worry about this disease. Let’s do the right thing to help protect our children from this devastating bacteria.

We seem to have the means to stop the spread of this disease, as evidenced by the fact that no additional cases have been reported from the Princeton campus since the use of the serogroup B vaccine there! We don’t want any more parents to receive a call like we did to hear that their child has died from contracting serogroup B meningitis.

Now that the FDA has licensed the first of the serogroup B meningococcal vaccines, we hope you will recommend them for adolescents and young adults. At the very least, they should be recommended for college students as they seem to be the largest group at risk. Like us, many parents and students may mistakenly believe that the previously licensed vaccines protected them against all of the serogroups that can affect our children.

In the coming weeks, several groups associated with Drexel University will be submitting letters supporting a recommendation for college-age adults. Some of them will be from Stephanie’s classmates who would like nothing more than to be protected from the bacteria that took the life of their dear friend. They want to be able to win the battle over the disease that Stephanie could not conquer. We are here on their behalf. And on behalf of her sister, Jacquelynn, who is now an only child and a freshman at one of the largest universities in the U.S.

It would be a tragedy, like Stephanie’s death, to see these vaccines approved by the FDA but not widely recommended.

Thank you for the opportunity to address you.”

A Big Step Forward and What Happens Next

30 Oct

In October 2000, the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) recommended that college students be informed that they were at higher risk for meningococcal disease and told there was a vaccine. It was the right thing to do—to protect our children.

In 2005, a new meningococcal vaccine became available and ACIP recommended it. It protected our adolescents and teens against serogroups A, C, W and Y. Again, it was the right thing to do.

Later, ACIP recommended a booster dose to ensure our kids stayed protected. It was the right thing to do.

But we aren’t done protecting our teens. I have heard over and over from parents whose children have suffered from serogroup B meningococcal disease, “I thought they were protected against meningitis,” they say. They believed their kids had the broadest possible protection.

I was thrilled yesterday (October 29) when the U.S. Food and Drug Administration (FDA) announced the approval of the first vaccine in the United States to prevent serogroup B meningococcal disease. I am hopeful that a second serogroup B vaccine, currently in priority review with the FDA, will also be approved soon. We now have the tools to protect our kids against five serogroups of meningococcal disease.  This includes all the serogroups that cause disease in the U.S.

Now that a vaccine is approved, we need to do the right thing again and routinely recommend serogroup B vaccination for adolescents and teens. We need to protect our children. It is what parents do. It is what society should do.

In the meantime, we know many people have questions about this new vaccine and what it means for their families. We hope this FAQ will help provide some answers:

1. How is this vaccine different from the meningococcal vaccines currently recommended by the CDC? If my children have already been vaccinated do they need to get this new vaccine?

Before now, vaccines licensed in the U.S. helped protect against four major strains of the disease: A, C, W and Y. Those vaccines do not prevent serogroup B meningococcal disease, which accounts for about one-third of U.S. cases. (To learn more about serogroup B meningococcal disease, please visit our website.)

To help protect against all serogroups, teens will need to receive:

  • Vaccination against serogroups A, C, W and Y. Recommended by the CDC for routine vaccination at age 11-12 with a booster dose at age 16.
  • Vaccination against serogroup B (the newly approved vaccine is a three-dose series, the vaccine still in review by the FDA will likely require two doses). The ACIP has not yet issued a recommendation for serogroup B meningococcal vaccination (see question five), however, now is a good time to start a conversation with a healthcare provider about it.

2. When will the vaccine be available? How do I get it?

The manufacturer is working to bring the vaccine to the U.S. but it may take two to three weeks for supply to become available. NMA encourages parents to start a conversation with your child’s healthcare provider about having them vaccinated against serogroup B.

3. Why wasn’t there a vaccine against serogroup B meningococcal disease before now?

Vaccines to protect against serogroup B meningococcal disease were challenging to develop because serogroup B behaves differently than other serogroups. Scientists overcame these challenges and two vaccines were developed. Because of recent serogroup B outbreaks and the devastating effects of meningococcal disease, the FDA granted both vaccines breakthrough therapy status, allowing for an accelerated review process. We expect the second serogroup B vaccine to be licensed soon.

For a great overview of the vaccine development, testing and regulation process visit the History of Vaccines website.

4. Why was the vaccine only licensed for individuals age 10-25?

The age group is based on the clinical trial data submitted by the vaccine manufacturer to the FDA.

5. What is the difference between licensure/approval and recommendation?

The FDA decides whether to approve use, known as licensure, after reviewing clinical data submitted by vaccine manufacturers. Once a vaccine is approved, the CDC’s ACIP, a group of medical and public health experts, makes recommendations on whether and how the vaccine should be used in the U.S. Once these recommendations are accepted by the Director of the CDC and published, they become part of the official immunization schedule.

To learn more about the ACIP and the recommendation process, click here.

6. What can I do to help protect children, teens and young adults from meningococcal disease?

Vaccination offers the best protection against meningococcal disease:

  • Make sure all tweens/teens get vaccinated against serogroups A, C, W and Y at age 11-12 and go back for a booster at age 16. Recent data showed that less than 30% of teens who had received the initial dose also received the recommended booster. We need to do better.
  • Now that there is an approved vaccine for serogroup B, we encourage you to tell your healthcare provider that you want it.

Even if you/your family members have been vaccinated against meningococcal disease you should learn the symptoms so you can watch for it in yourself or in others. We also have resources you can share to help educate friends, family or patients.

Finally, you can follow NMA on Facebook and Twitter where we will let you know when there are opportunities to help raise awareness of this disease and advocate for its prevention.

Recent Cases of Serogroup B Meningococcal Disease Reinforce Need for U.S. Vaccine: A Statement from the National Meningitis Association

24 Sep

Every case of serogroup B meningococcal disease, like the recent case at Georgetown University, is an important reminder that there is an unmet public health need in the prevention of bacterial meningitis in the U.S. Please take a moment to watch this important message from NMA President Lynn Bozof.

Follow

Get every new post delivered to your Inbox.

Join 16,191 other followers